As of Friday close, Inovio Pharmaceuticals Inc.’s (NASDAQ:INO) stock was down -$0.04, moving down -3.54 percent to $1.09. The average number of shares traded per day over the past five days has been 3,604,820 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.0400 fall in that time frame. In the last twenty days, the average volume was 3,991,590, while in the previous 50 days, it was 4,383,324.
Since last month, INO stock retreated -29.68%. Shares of the company fell to $1.0900 on 03/17/23, the lowest level in the past month. A 52-week high of $4.00 was reached on 01/13/23 after having rallying from a 52-week low of $1.09. Since the beginning of this year, INO’s stock price has dropped by -30.13% or -$0.4700, and marked a new high 7 times. However, the stock has declined by -72.75% since its 52-week high.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
INO stock investors should be aware that Inovio Pharmaceuticals Inc. (INO) stock had its last reported insider trading activity 5 days ago on Mar 13. Weiner David B., the Director of the company, disposed of 5,833 shares for $1.15 on Mar 13. It resulted in a $6,708 divestment by the insider. Weiner David B. sold 11,668 shares at an average price of $1.28 on Feb 27. The insider now owns 904,291 shares following the transaction. On Aug 11, Director Weiner David B. sold 11,875 shares at $2.66 apiece. The transaction was valued at $31,588.
The stock’s beta is 1.14. Besides these, the trailing price-to-sales (P/S) ratio of 28.02, the price-to-book (PB) ratio of 1.22.
The latest dividend of $0.0690 per share was paid out, remained unchanged from last year’s $0.0690.
In the three months ended December 30, Inovio Pharmaceuticals Inc.’s quick ratio stood at 3.30, while its current ratio was 3.30, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending December 30 was 0.07, and the total debt-to-equity ratio was 0.07. Based on annual data, INO earned $277.84 million in gross profit and brought in $10.26 million in revenue.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. INO’s revenue rose 90.77% to $1.64 million during the quarter, while net income inched up to $11.48 million. While analysts expected Inovio Pharmaceuticals Inc. to report -$0.17 quarterly earnings, the actual figure was -$0.21 per share, beating the consensus estimate by -23.50%. During the quarter, the company generated -$55.33 million in EBITDA. The liabilities of Inovio Pharmaceuticals Inc. were 126.17 million at the end of its most recent quarter ended December 30, and its total debt was $32.07 million. The value of shareholders’ equity is $260.13 million.
This quick technical analysis looks at Inovio Pharmaceuticals Inc.’s (INO) price momentum. With a historical volatility rate of 48.88%, the RSI 9-day stood at 28.01% on 17 March.
With respect to its five-day moving average, the current Inovio Pharmaceuticals Inc. price is down by -3.54% percent or -$0.0400. At present, INO shares trade -27.81% below its 20-day simple moving average and -38.42% percent below its 100-day simple moving average. However, the stock is currently trading approximately -33.13% below its SMA50 and -41.71% below its SMA200.
Stochastic coefficient K was 20.90% and Stochastic coefficient D was 22.63%, while ATR was 0.0778. Given the Stochastic reading of 0.00% for the 14-day period, the RSI (14) reading has been calculated as 30.62%. As of today, the MACD Oscillator reading stands at -0.0289, while the 14-day reading stands at -0.0695.
Inovio Pharmaceuticals Inc. downgraded its rating on Inovio Pharmaceuticals Inc. (NASDAQ: INO) to a Hold in a note to investors on November 09, 2022. The analysts firm previously had a Buy rating on the stock.Inovio Pharmaceuticals Inc. (INO) has been rated Hold by analysts. According to 0 brokerage firms, INO is a sell, and 4 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 0 analysts rate Inovio Pharmaceuticals Inc. stock as buy, with 0 recommending it as overweight.